Table 2.
Tacrolimus (n = 168) | Sirolimus (n = 29) | |
---|---|---|
Progression to RRT, n (%) | 0 | 0 |
Biopsy-proven acute cellular rejection, n (%) | 24 (14)b | 10 (34)b |
Graft survival 1 year after transplant, % | 90.7c | 82.6c |
Patient survival 1 year after transplant, % | 95.6b,c | 84.8b,c |
aOutlier detected using Grubb's test.
b P < 0.05 between treatment groups.
cSurvival analysis: n = 182 for tacrolimus group and n = 46 for sirolimus group.